FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

eToro Strengthens Crypto Portfolio with Zengo Acquisition

Deal expands eToro's offerings in the cryptocurrency sector.Highlights: eToro is acquiring crypto wallet Zengo to expand its services.The...
FinTech

Revolut Launches Platform to Streamline Overseas Talent Hiring

Revolut's new service aims to simplify global recruitment for businesses.Highlights: Revolut launches a platform for hiring overseas talent.The...
FinTech

Revolut Strengthens Business Recruitment Platform in New Markets

The fintech giant expands its offerings targeting recruitment needs globally.Highlights: Revolut enhances its platform for business recruitment.The expansion...
FinTech

UniCredit Selects Slate to Strengthen Retail Investment Services

The partnership aims to enhance digital investment options for customers.Highlights: UniCredit partners with Slate for enhanced retail investment...